For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 102,928 | |||
| General and administrative | 29,834 | |||
| Total operating expenses | 132,762 | |||
| Loss from operations | -132,762 | |||
| Interest and other income, net | 12,815 | |||
| Total other income | 12,815 | |||
| Net loss | -119,947 | |||
| Unrealized gain (loss) on marketable securities available-for-sale, net | -377 | |||
| Comprehensive loss | -120,324 | |||
| Basic EPS | -2.01 | |||
| Diluted EPS | -2.01 | |||
| Basic Average Shares | 59,602,328 | |||
| Diluted Average Shares | 59,602,328 | |||
Tyra Biosciences, Inc. (TYRA)
Tyra Biosciences, Inc. (TYRA)